News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
GMM Pfaudler US completes acquisition of MixPro
Subscribe To Our Newsletter & Stay Updated
